The results of conservative treatment of oxalate urolithiasis in children;Wyniki leczenia zachowawczego kamicy szczawianowej u dzieci

Polski Merkuriusz Lekarski

Volumn 15, Issue 85, 2003, Pages 51-54

  Rogowska Kalisz, Anna ^a   Tkaczyk, Marcin ^a   Bilińska, Wiesława ^a   Nowicki, Michał ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Children; Hyperoxaluria; Oxalate urolithiasis

Indexed keywords

CITRIC ACID; LACTIC ACID; MAGNESIUM; OXALIC ACID; PYRIDOXINE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; HEMATURIA; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPERURICOSURIA; SCHOOL CHILD; TREATMENT OUTCOME; UROLITHIASIS; VITAMIN SUPPLEMENTATION;

ADOLESCENT; CHILD; CITRATES; FATTY ACIDS; FEMALE; HUMANS; HYPEROXALURIA; MAGNESIUM OXIDE; MALE; OXALATES; URINARY CALCULI; VITAMIN B 6;

EID: 0042736483     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Akhan O. i wsp.: Systemic oxalosis: pathognomonic renal and specific extrarenal findings on US and CT. Pediatr. Radiol., 1995, 25, 15-16.
2. Batinic D. i wsp.: Value of the urinary stone promoters/inhibitors ratios in the estimation of the risk of urolithiasis. J. Chem. Inf. Comput. Sci., 2000, 40, 607-610.
3. Campieri C. i wsp.: Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int., 2001, 60, 1097-1105.
4. Castello-Girona F. i wsp.: Results of treatment with oral citrate and pyridoxine in patients with primary hyperoxaluria type 1. Ann. Esp. Pediatr., 1999, 50, 397-401.
5. Cochat P. i wsp.: Primary hyperoxaluria in infants: medical, ethical, and economic issues. J. Pediatr., 1999, 135, 746-750.
6. Cochat P. i wsp.: Combined liver-kidney transplantation in primary hyperoxaluria type 1. Eur. J. Pediatr., 1999, 158, suppl. 2, 75-80.
7. Cramer S.D. i wsp.: The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoksaluria type II. Hum. Mol. Genet., 1999, 8, 2063-2069.
8. Egoshi K. i wsp.: The evaluation of methods for determinations of urinary oxalate. Nippon Hinyokika Gakkai Zasshi, 1999, 90, 675-680.
9. Eusufzai S.: Bile acid malabsorption mechanism and treatment. Dig. Dis. 1995, 13, 312-321.
10. Fryczkowski M.: Kamica moczowa. W: Podstawy urologii. (red. Fryczkowski M.). Śla̧ska Akademia Medyczna, Katowice. 2000, 80-92.
11. Furth S.L. i wsp.: Risk factors for urolithiasis in children on the ketogenic diet. Pediatr. Nephrol. 2000, 15, 125-128.
12. Goldfarb D.S. i wsp.: Prevention of recurrent nephrolithiasis. Am. Fam. Physican., 1999, 60, 2269-2276.
13. Goldfarb D.S. i wsp.: Effect of grapefruit juice on urinary lithogenicity. J. Urol., 2001, 166, 263-267.
14. Goła̧bek B. i wsp.: Ocena skuteczności leczenia i profilaktyki kamicy ukאadu moczowego u dzieci. Med. Wieku Rozw., 1999, 3 259-280.
15. Jung A.: Kamica układu moczowego - stara choroba, nowe pogla̧dy. Pol. Merkuriusz Lek., 2000, 8, 167-169.
16. Marangella M. i wsp.: Bony content of oxalate in patients with primary hyperoxaluria or oxalosis - unrelated renal failure. Kidney Int., 1995, 48, 182-187.
17. Miyake O. i wsp.: High urinary excretion level of citrate and magnesium in children: potential etiology for the reduced incidence of pediatric urolithiasis. Urol. Res., 1998, 26, 209-213.
18. Mole D.R. i wsp.: Renal complications of jejuno-ileal bypass for obesity. Q. J. M., 2001, 94 69-77.
19. Morozumi M. i wsp.: Impact of dietary calcium and oxalate ratio on urinary stone formation in rats. Mol. Urol., 2000, 4, 313-320.
20. Parks J,H. i wsp.: Pathogenesis and treatment of calcium stones. Semin. Nephrol., 1996, 16 398-411.
21. Schwille P.O. i wsp.: Ascorbic acid in idiopathic recurrent calcium urolithiasis in humans - does it have an abettor role in oxalate, and calcium oxalate crystallization? Urol. Res., 2000, 28 167-177.
22. Smith L.H.: Enteric hyperoksaluria and other hyperoxaluric status. Nephrology, 1980, 5, 43-71.
23. Takei K. i wsp.: Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Urol. Int. 1998, 61, 192-195.
24. Thervet E. i wsp.: Is there a place for isolated renal transplantation in the treatment of primary hyperoxaluria type 1? Experience from Paris. Nephrol. Dial. Transplant., 1995, 10, suppl. 8, 838-841.
25. Toblli J.E. i wsp.: Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats. Hypertension, 1999, 34, 854-858.
26. Toblli J.E. i wsp.: Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria. J. Urol., 2001, 166, 275-280.
27. Toussaint C.: Pyridoxine-responsive PH1, treatment. J. Nephrol. 1998, 11, suppl., 149-150.
28. Turner M.A. i wsp.: Oxalate and calcium excretion in cystic fibrosis. Arch. Dis. Child., 2000, 83, 244-247.
29. Wu D.S. i wsp.: Indinavir urolithiasis. Curr. Opin. Urol., 2000, 10, 557-561.
30. Yagisawa T. i wsp.: Comparison of comprehensive and limited metabolic evaluations in the treatment of patients with recurrent calcium urolithiasis. J. Urol., 1999, 161, 1449-1452.